SCHEMBL7200563

SCHEMBL7200563

NC(=O)N1CCC(S(=O)(=O)c2ccc(OCc3cccc(Cl)c3)cc2)C(O)(C(=O)O)C1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 8/20 0.57
MMP13 P45452 6/20 0.57
ADAM17 P78536 2/20 0.46
S1PR1 P21453 1/20 0.45
S1PR5 Q9H228 1/20 0.45
ADAMTS4 O75173 4/20 0.45
RXRA P19793 1/20 0.44
RXRB P28702 1/20 0.44
RXRG P48443 1/20 0.44
BCL2 P10415 1/20 0.44
BID P55957 1/20 0.44
MCL1 Q07820 1/20 0.44
MAPK1 P28482 1/20 0.43
MMP2 P08253 2/20 0.42
MMP3 P08254 1/20 0.42
MMP9 P14780 1/20 0.42
MMP12 P39900 1/20 0.42
MMP14 P50281 1/20 0.42
MAOA P21397 2/20 0.41
MAOB P27338 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7203984 0.90 MMP1 (0.45) MMP1MMP13ADAM17ADAMTS4MMP2
SCHEMBL7201593 0.90 MAOB (0.49) MMP1MMP13ADAM17MMP2MMP9
SCHEMBL7201801 0.90 MMP1 (0.57) MMP1MMP13ADAM17ADAMTS4MAOB
SCHEMBL7205347 0.89 MMP1 (0.56) MMP1MMP13ADAM17ADAMTS4MMP2
SCHEMBL7201220 0.89 MMP1 (0.47) MMP1MMP13ADAM17MMP2MMP9
SCHEMBL7199646 0.86 MMP1 (0.43) MMP1MMP13MMP2MMP3MMP9
SCHEMBL7200542 0.84 ADAMTS4 (0.42) MMP1MMP13ADAMTS4MMP3MMP9
SCHEMBL7208181 0.84 MMP13 (0.56) MMP1MMP13ADAM17ADAMTS4MMP2
SCHEMBL7205420 0.84 MMP1 (0.45) MMP1MMP13ADAM17S1PR5ADAMTS4
SCHEMBL7205273 0.84 MMP1 (0.56) MMP1MMP13ADAM17ADAMTS4MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 MMP1 8/4885MMP13 4/4885ADAM17 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.